ホーム › 多発性骨髄腫 › アラバマ州 › Birmingham
Birmingham、ALにおける多発性骨髄腫の臨床試験
Birminghamとその周辺地域（約30マイル以内）の拠点で、多発性骨髄腫に関する18件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
被験者募集中第1/2相
- University of Alabama At Birmingham Hospital, Birmingham
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第3相
- Alabama Oncology, Birmingham
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第2相
- University of Alabama Birmingham, Birmingham
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1/2相
- University of Alabama at Birmingham Hospital, Birmingham
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
被験者募集中第2相
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
被験者募集中第3相
- University of Alabama at Birmingham, Birmingham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第2相
- University of Alabama at Birmingham, Birmingham
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
被験者募集中第1/2相
- University of Alabama at Birmingham, Birmingham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
被験者募集中第1/2相
- Research Site, Birmingham
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
被験者募集中第1相
- University of Alabama at Birmingham, Birmingham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
被験者募集中第2相
- University of Alabama at Birmingham, Birmingham
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
被験者募集中第1相
- University of Alabama at Birmingham, Birmingham
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
被験者募集中第1相
- University of Alabama at Birmingham, Birmingham
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
被験者募集中第2相
- University of Alabama at Birmingham, Birmingham
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
被験者募集中
- Kirklin Clinic of UAB Hospital, Birmingham
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
被験者募集中観察研究
- Kirklin Clinic of UAB Hospital, Birmingham
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
被験者募集中第1相
- University of Alabama at Birmingham, Birmingham
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1/2相
- UAB Comprehensive Cancer Center, Birmingham
他の都市における多発性骨髄腫の試験
- New York City, NY60件の研究
- Boston, MA42件の研究
- Atlanta, GA41件の研究
- Houston, TX38件の研究
- Durham, NC37件の研究
- Nashville, TN32件の研究
- Denver, CO27件の研究
- Rochester, MN24件の研究
- St. Louis, MO24件の研究
- Columbus, OH24件の研究
- Baldwin Park, CA23件の研究
- Chicago, IL22件の研究
Birminghamにおける他の研究
- がん（全種類）30件の研究
- 乳がん24件の研究
- 肥満症23件の研究
- 卵巣がん23件の研究
- 非小細胞肺癌22件の研究
- 急性骨髄性白血病21件の研究
- COPD17件の研究
- 心血管疾患17件の研究
- 過体重16件の研究
- 子宮内膜がん16件の研究
- 2型糖尿病16件の研究
- 嚢胞性線維症16件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。